About MiRagen
MiRagen is a company based in Boulder (United States) founded in 2007 by Sanjoy Mahanty, William Marshall, and Bruce Booth.. MiRagen has raised $111.29 million across 19 funding rounds from investors including Fidelity Investments, Citadel and Atlas Venture. The company has 92 employees as of December 31, 2022. MiRagen has completed 2 acquisitions, including Signal Genetics and Viridian Bio. MiRagen offers products and services including TED Programs and FcRn Portfolio. MiRagen operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Boulder, United States
- Employees 92 as on 31 Dec, 2022
- Founders Sanjoy Mahanty, William Marshall, Bruce Booth
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Miragen Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$111.29 M (USD)
in 19 rounds
-
Latest Funding Round
$91 M (USD), Post-IPO
Oct 28, 2020
-
Investors
Fidelity Investments
& 20 more
-
Employee Count
92
as on Dec 31, 2022
-
Investments & Acquisitions
Signal Genetics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MiRagen
MiRagen offers a comprehensive portfolio of products and services, including TED Programs and FcRn Portfolio. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments for thyroid eye disease through antibody engineering.
Focuses on therapies for autoimmune conditions via optimized antibodies.
Unlock access to complete
Unlock access to complete
Funding Insights of MiRagen
MiRagen has successfully raised a total of $111.29M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $91 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Post-IPO — $91.0M
-
First Round
First Round
(14 Mar 2008)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Post-IPO - MiRagen | Valuation |
investors |
|
| Oct, 2019 | Amount | Post-IPO - MiRagen | Valuation |
investors |
|
| Nov, 2017 | Amount | Series C - MiRagen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MiRagen
MiRagen has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Citadel and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MiRagen
MiRagen has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Signal Genetics and Viridian Bio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Providing aid in translating basic science research into products
|
2019 | ||||
|
Microarray-based prognostic tests are provided for disease risk assessment.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - MiRagen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Miragen Comparisons
Competitors of MiRagen
MiRagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Miragen
Frequently Asked Questions about MiRagen
When was MiRagen founded?
MiRagen was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Where is MiRagen located?
MiRagen is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Is MiRagen a funded company?
MiRagen is a funded company, having raised a total of $111.29M across 19 funding rounds to date. The company's 1st funding round was a Series C of $172.29K, raised on Mar 14, 2008.
How many employees does MiRagen have?
As of Dec 31, 2022, the latest employee count at MiRagen is 92.
What does MiRagen do?
MiRagen was established in 2007 in Boulder, United States, within the biotechnology sector. MicroRNA-based therapeutic solutions are created for addressing various diseases, including haematological malignancies, neurodegeneration, and ischemia. The drug pipeline features candidates like MRG-106, MRG-107, and MRG-110. Co-founders such as Sanjoy Mahanty, William Marshall, and Bruce Booth contribute to leadership in these operations.
Who are the top competitors of MiRagen?
MiRagen's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does MiRagen offer?
MiRagen offers TED Programs and FcRn Portfolio.
How many acquisitions has MiRagen made?
MiRagen has made 2 acquisitions, including Signal Genetics, and Viridian Bio.
Who are MiRagen's investors?
MiRagen has 21 investors. Key investors include Fidelity Investments, Citadel, Atlas Venture, Perceptive Advisors, and Fairmount Funds Management.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.